Cidara Therapeutics (CDTX) announced that the first participants have been dosed in its Phase 3 trial to evaluate the safety and efficacy of CD388, a non-vaccine preventative of seasonal influenza, in populations at high-risk for complications of influenza. Based on feedback from the FDA, the study population has been expanded to also include generally healthy adults over 65 years old with no specific co-morbidities in addition to other high-risk populations with certain comorbidities and immune compromised status.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDTX:
- Cidara Therapeutics Expands Phase 3 Trial for CD388
- Cidara Therapeutics price target raised to $153 from $66 at Citizens JMP
- Cidara Therapeutics price target raised to $100 from $74 at Needham
- Cidara Therapeutics’ Accelerated Path to BLA Approval and Expanded Market Potential Boosts Buy Rating
- Accelerated Phase 3 Study and Expanded Market Potential Make Cidara Therapeutics a Strong Buy